GE HealthCare’s (NASDAQ:GEHC) Q3 2026 sales beat estimates
GE HealthCare reported Q3 2026 revenue of $5.51B, exceeding estimates by 3% and growing 7.2% YoY. Adjusted EPS was $1.34, beating estimates by 11.3%. The company raised its full-year adjusted EPS guidance to $5 at the midpoint. Operating and free cash flow margins improved to 14.6% and 14.4%, respectively, up from the prior year.
How this was made
The 30-second read
Why it matters
The beat and raised EPS guidance are likely to drive buying interest.
Market read
Strong earnings and guidance raise for a large-cap healthcare company.
What to watch
Potential supply chain constraints or regulatory risks not discussed in the release.
Background
GE HealthCare reported Q3 2026 results with revenue of $5.51B versus $5.35B consensus and EPS of $1.34 versus $1.20 consensus.
Ticker impact
Q3 2026 sales beat estimates and management raised full-year adjusted EPS guidance to $5.
likely upward pressure as the market prices in the beat and higher guidance.
Revenue and EPS both exceeded consensus and guidance was increased, a strong catalyst for the stock.
Market effects
Healthcare equipment sector may see broader optimism from a large-cap beat.
U.S. markets could open higher on the news.
Limited to investors tracking U.S. healthcare stocks.
Counterpoint
If the beat is already priced in, the stock could face short-term profit taking.
Key entities
- companyGE HealthCare
U.S.-listed healthcare equipment and services provider.
